...
search icon
zyme-img

Zymeworks Inc. Common Stock, Common Stock

ZYME

NSQ

$11.53

+$0.28

(2.49%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$765.35M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
383.28K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.17
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.97 L
$17.7 H
$11.53

About Zymeworks Inc. Common Stock, Common Stock

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameZYMESectorS&P500
1-Week Return22.14%1.04%0.24%
1-Month Return-8.35%-7.14%-7.32%
3-Month Return-16.93%-2.78%-12.05%
6-Month Return-14.4%-10.56%-9.73%
1-Year Return30.28%-1.55%5.05%
3-Year Return115.51%-0.6%20.03%
5-Year Return-68.54%35.24%83.31%
10-Year Return-11.31%85.96%153.54%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue38.95M26.68M412.48M76.01M76.30M[{"date":"2020-12-31","value":9.44,"profit":true},{"date":"2021-12-31","value":6.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":18.43,"profit":true},{"date":"2024-12-31","value":18.5,"profit":true}]
Cost of Revenue170.90M199.54M208.70M142.99M-[{"date":"2020-12-31","value":81.88,"profit":true},{"date":"2021-12-31","value":95.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":68.51,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit38.95M26.68M412.48M(66.98M)76.30M[{"date":"2020-12-31","value":9.44,"profit":true},{"date":"2021-12-31","value":6.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-16.24,"profit":false},{"date":"2024-12-31","value":18.5,"profit":true}]
Gross Margin100.00%100.00%100.00%(88.11%)100.00%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-88.11,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses226.42M242.31M281.95M71.08M213.41M[{"date":"2020-12-31","value":80.3,"profit":true},{"date":"2021-12-31","value":85.94,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":25.21,"profit":true},{"date":"2024-12-31","value":75.69,"profit":true}]
Operating Income(187.47M)(215.63M)130.53M(138.05M)(137.11M)[{"date":"2020-12-31","value":-143.62,"profit":false},{"date":"2021-12-31","value":-165.2,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-105.77,"profit":false},{"date":"2024-12-31","value":-105.04,"profit":false}]
Total Non-Operating Income/Expense13.04M5.78M8.30M38.52M40.44M[{"date":"2020-12-31","value":32.25,"profit":true},{"date":"2021-12-31","value":14.29,"profit":true},{"date":"2022-12-31","value":20.53,"profit":true},{"date":"2023-12-31","value":95.24,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(180.12M)(212.36M)135.23M(119.24M)(116.61M)[{"date":"2020-12-31","value":-133.19,"profit":false},{"date":"2021-12-31","value":-157.03,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-88.17,"profit":false},{"date":"2024-12-31","value":-86.23,"profit":false}]
Income Taxes429.00K(516.00K)10.89M(568.00K)6.08M[{"date":"2020-12-31","value":3.94,"profit":true},{"date":"2021-12-31","value":-4.74,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-5.21,"profit":false},{"date":"2024-12-31","value":55.85,"profit":true}]
Income After Taxes(180.55M)(211.84M)124.34M(118.67M)(122.69M)[{"date":"2020-12-31","value":-145.21,"profit":false},{"date":"2021-12-31","value":-170.37,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-95.44,"profit":false},{"date":"2024-12-31","value":-98.68,"profit":false}]
Income From Continuous Operations(180.55M)(211.84M)124.34M(118.67M)(122.69M)[{"date":"2020-12-31","value":-145.21,"profit":false},{"date":"2021-12-31","value":-170.37,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-95.44,"profit":false},{"date":"2024-12-31","value":-98.68,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(180.55M)(211.84M)124.34M(118.67M)(122.69M)[{"date":"2020-12-31","value":-145.21,"profit":false},{"date":"2021-12-31","value":-170.37,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-95.44,"profit":false},{"date":"2024-12-31","value":-98.68,"profit":false}]
EPS (Diluted)(3.58)(4.11)1.93(1.73)(1.39)[{"date":"2020-12-31","value":-185.49,"profit":false},{"date":"2021-12-31","value":-212.95,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-89.64,"profit":false},{"date":"2024-12-31","value":-72.02,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ZYME
Cash Ratio 2.56
Current Ratio 3.40

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ZYME
ROA (LTM) -14.57%
ROE (LTM) -30.54%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ZYME
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ZYME
Trailing PE NM
Forward PE NM
P/S (TTM) 10.51
P/B 2.37
Price/FCF NM
EV/R 7.80
EV/Ebitda 0.34
PEG NM

FAQs

What is Zymeworks Inc. Common Stock share price today?

Zymeworks Inc. Common Stock (ZYME) share price today is $11.53

Can Indians buy Zymeworks Inc. Common Stock shares?

Yes, Indians can buy shares of Zymeworks Inc. Common Stock (ZYME) on Vested. To buy Zymeworks Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZYME stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Zymeworks Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Zymeworks Inc. Common Stock (ZYME) via the Vested app. You can start investing in Zymeworks Inc. Common Stock (ZYME) with a minimum investment of $1.

How to invest in Zymeworks Inc. Common Stock shares from India?

You can invest in shares of Zymeworks Inc. Common Stock (ZYME) via Vested in three simple steps:

  • Click on Sign Up or Invest in ZYME stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Zymeworks Inc. Common Stock shares
What is Zymeworks Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Zymeworks Inc. Common Stock (ZYME) is $17.7. The 52-week low price of Zymeworks Inc. Common Stock (ZYME) is $7.97.

What is Zymeworks Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Zymeworks Inc. Common Stock (ZYME) is 2.37

What is the Market Cap of Zymeworks Inc. Common Stock?

The market capitalization of Zymeworks Inc. Common Stock (ZYME) is $765.35M

What is Zymeworks Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Zymeworks Inc. Common Stock is ZYME

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top